Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Overview
Explore Alnylam Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
40.8B
P/E Ratio
128.58
EPS (TTM)
$2.34
ROE
0.90%
ALNY Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Alnylam Pharmaceuticals, Inc. (ALNY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 41.30, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $361.64.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 128.58 and a market capitalization of 40.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.